Gastro Congress Market Analysis and Reports | France Conference Series

Market Analysis - Gastro Congress 2017

Market Analysis

Future Projection: The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%. Although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium and Remicade, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth.

North America is the largest market of Gastrointestinal Disorder Therapeutics due to increasing number of GI disorders. Now, launch of advanced drugs by key players doubled the uptake of the drugs by consumers will enhance the market to the highest. Europe is second largest market of the Gastrointestinal Therapeutics. Key players are driving the market with innovative drugs attracts customers through which they are filling their product pipelines. By 2022 Europe grows to Compound Annual Growth Rate (CAGR) ranging from 1% to 3%. GI Anti-inflammatory drugs estimated to drive from 1 to 5% and will be the fastest driving country during the forecast period. Asia Pacific is the emerging market of gastrointestinal disorder therapeutics as research says there is drive in the number customers incident to peptic ulcer, Crohn’s disease, Acid related diseases, GI bleeding, Irritable bowel syndrome, ulcerative colitis.

FDA Approved Drugs for Gastroenterology

Drugs Approved in 2016

Zinplava (bezlotoxumab); Merck; for the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016

Drugs Approved in 2015

-Avycaz (ceftazidime-avibactam); Actavis; for the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015

-Cholbam (cholic acid); Asklepion Pharmaceuticals; for the treatment of bile acid synthesis and peroxisomal disorders, Approved March 2015

-Lonsurf (trifluridine and tipiracil); Taiho Oncology; for the treatment of metastatic colorectal cancer, Approved September 2015

-Onivyde (irinotecan liposome injection); Merrimack; for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Approved October 2015

-Varubi (rolapitant); Tesaro; for the prevention of delayed nausea and vomiting associated with chemotherapy, Approved September 2015

-Viberzi (eluxadoline); Actavis; for the treatment of irritable bowel syndrome with diarrhea, Approved May 2015

-Xifaxan (rifaximin); Salix Pharmaceuticals; for the treatment of irritable bowel syndrome with diarrhea, Approved May 2015

 

Drugs Approved in 2014

-Akynzeo (netupitant and palonosetron); Helsinn; for the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014

-Cyramza (ramucirumab); Eli Lilly; for the treatment of gastric cancer, Approved April 2014

-Entyvio (vedolizumab); Millenium Pharmaceuticals; for the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014

-Movantik (naloxegol); AstraZeneca; for the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014

-Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals; for the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014

 

Drugs Approved in 2013

-Simponi (golimumab); Janssen Biotech; for the treatment of ulcerative colitis, Aproved May 2013

-Stivarga (regorafenib); Bayer; for the treatment of gastrointestinal stromal tumor, Approved February 2013

-Uceris (budesonide); Santarus; for the treatment of ulcerative colitis, Approved January 2013

 

Drugs Approved in 2012

-Elelyso (taliglucerase alfa); Pfizer; for the treatment of Gaucher disease, Approved May 2012

-Gattex (teduglutide); NPS Pharmaceuticals; for the treatment of short bowel syndrome, Approved December 2012

-Linzess (linaclotide); forest Labs and Ironwood Pharmaceuticals; for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012

-Mytesi (crofelemer); Napo Pharmaceuticals; for the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012

-Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals; for the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012

-Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma; for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012

-Viokace (pancrelipase) tablets; Aptalis Pharma; for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012

-Xtandi (enzalutamide); Medivation; for the treatment of metastatic castration-resistant prostate cancer, Approved August 2012

-Zaltrap (ziv-aflibercept); Sanofi-aventis; for the treatment of metastatic colorectal cancer, Approved August 2012

 

Drugs Approved in 2011

-Afinitor (everolimus); Novartis; for the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011

-Dificid (fidaxomicin); Optimer Pharmaceuticals; for the treatment of Clostridium difficile-associated diarrhea, Approved May 2011

-Duexis (ibuprofen and famotidine); Horizon Pharma; for the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011

-Incivek (telaprevir); Vertex Pharmaceuticals; for the treatment of genotype 1 chronic hepatitis C, Approved May 2011

-Rectiv (nitroglycerin) ointment 0.4%; ProStrakan; for the treatment of chronic anal fissure, Approved June 2011

-Sutent (sunitinib malate); Pfizer; for the treatment of pancreatic neuroendocrine tumors, Approved May 2011

-Victrelis (boceprevir); Merck; for the treatment of chronic hepatitis C genotype 1, Approved May 2011

 

Drugs Approved in 2010

-Herceptin (trastuzumab); Genentech; for the treatment of gastric cancer, Approved October 2010

-Pancreaze (pancrelipase); Johnson & Johnson; for the treatment of exocrine pancreatic insufficiency, Approved April of 2010

-Vimovo (naproxen + esomeprazole); AstraZeneca; for the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010

-Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals; for the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010

Conference Highlights:

  • Gastrointestinal Complications in Diabetes
  • Gastroenterologist in Managing Obesity
  • Microbiota in health and gastrointestinal disease
  • Diets/Dietary habits (Nutrition) and Gastrointestinal Disorders:
  • Gastroenterology and Pharmacotherapy
  • Palliative Gastroenterology
  • Digestive Diseases
  • Probiotics in Gastrointestinal Disorders
  • Clinical Advances in Liver Diseases
  • Pediatric Gastroenterology
  • Genetics and Molecular Biology in Gastroenterology
  • Gastrointestinal Cancers
  • Neuro Gastroenterology
  • Psychiatry, psychotherapy and Gastroenterology
  • Physiotherapy in Gastroenterology
  • Gastroenterology and Pregnancy

Major Gastroenterology Associations and societies around the Globe:

  • American Gastroenterological Association
  • Canadian Association of Gastroenterology
  • European Association for Gastroenterology and Endoscopy
  • Ontario Association of Gastroenterology
  • European Association for the Study of the Liver
  • The Asian Pacific Association for the Study of the Liver
  • World Gastroenterology Organization
  • American Society for Gastrointestinal Endoscopy
  • Society of Pediatric Gastroenterologists and Dieticians
  • NC Society of Gastroenterology
  • Emirates Gastroenterology and Hepatology Society
  • SCSG - Southern California Society of Gastroenterology;
  • Florida Gastroenterological Society
  • British Society of Gastroenterology
  • United European Gastroenterology
  • Gastroenterological Society of Australia

 

For more details contact Senior Event Manager

E: gastrocongress@gastroconferences.com; gastrocongress@conferenceseries.net

T: 650-268-9744 | M: 702-508-5202

LinkedIn: https://www.linkedin.com/in/sophia-williams-gastro/

 

Gastro Congress 2017 Conference website is attracting 30000+ Public Health Professionals, Gastroenterologists, Hepatologists, Endocrinologists, Endoscopy Experts, online visitors ranging from Researchers, Academicians and Business professionals, who are working in this field. This unique opportunity that we extend to our speakers and attendees is not being offered by any other conference organizers.

Gastro Congress 2017 mainly focusses on different treatment modalities by which a case can be drived to curate. Through this the abstracts and research profiles of our speakers and organizing committee members getting global visibility which is an additional feature that you would be receiving in addition to networking opportunities before, during and after the conference.